[Featured Stock] HK Innoen, Expected Earnings Growth, Up Over 9%

The stock price of HK Innoen, whose earnings estimates have been revised upward, showed strength on the 9th. As of 9:50 a.m. that day, HK Innoen was trading at 39,700 won, up 3,400 won (9.37%) from the previous trading day.

On the same day, Kyobo Securities maintained a buy rating and a target price of 49,000 won. Jeonghyun Kim, a researcher at Kyobo Securities, said, "Sales in the second quarter of this year are expected to be 223.9 billion won, an increase of 9.5% compared to the same period last year, and operating profit is expected to rise 47.7% to 22.6 billion won," adding, "This is a performance that exceeds market expectations."

He stated, "Although in-hospital prescriptions were expected to decrease due to the medical sector strike, profitability is expected to improve as sales of intravenous fluids grow. Distribution fees from the technology transfer of IM Biologics are reflected, and sales of K-CAB (K-Cap) will show significant growth compared to the same period last year by demonstrating both growth in out-of-hospital prescription performance and the effect of reduced commission rates."

He added, "Overall performance continues the improvement trend expected by the market at the beginning of the year. For further corporate value enhancement, upward momentum through research and development (R&D) is necessary," and "If efficacy is proven in the U.S. clinical trials of the gastroesophageal reflux disease treatment K-CAB, expectations for entry into the U.S. market will increase, raising the stock price level relative to corporate value."